The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments, Clinical chemistry, vol.59, issue.6, pp.892-902, 2013. ,
, Proc Natl Acad Sci U S A, vol.96, issue.16, p.17763, 1999.
Quantitation of targets for PCR by use of limiting dilution, BioTechniques, vol.13, issue.3, pp.444-453, 1992. ,
Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, issue.7, pp.405-421, 2012. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299585
Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, issue.5, 2015. ,
Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR, Epub 2015/04/18, 2015. ,
Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer, Epub 2015/05/17, vol.61, p.25979954, 2015. ,
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clinical chemistry, vol.59, issue.12, 2013. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299581
Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma, J Mol Diagn, 2015. ,
Digital PCR compartmentalization I. Single-molecule detection of rare mutations, vol.31, pp.84-92, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299576
,
, Medecine, vol.31, issue.2, pp.180-186, 2015.
Circulating tumor DNA as a liquid biopsy for cancer, Clinical chemistry, vol.61, issue.1, pp.112-135, 2015. ,
Circulating Cell-Free Tumour DNA in the Management of Cancer, Int J Mol Sci, vol.16, issue.6, p.4490543, 2015. ,
Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Scientific reports, vol.5, 2015. ,
, , p.4476039
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, vol.9, p.4224589, 2014. ,
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Lung Cancer, Epub 2015/07/ 05, 2015. ,
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer, J Clin Oncol, vol.31, issue.31, p.3805932, 2013. ,
Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance, Lung Cancer, vol.80, issue.3, p.23485129, 2013. ,
Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients, Clin Cancer Res, vol.15, issue.6, pp.2076-84, 2009. ,
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors, vol.20, pp.12-28, 2015. ,
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, vol.26, issue.3, pp.374-383, 2008. ,
URL : https://hal.archives-ouvertes.fr/hal-00363737
Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Medical Oncology / ESMO, vol.24, issue.5, pp.1267-73, 2013. ,
KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, issue.8, pp.3992-3997, 2006. ,
The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations, OncoTargets and therapy, vol.9, p.4768896, 2016. ,
Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma, Clinical chemistry, vol.61, issue.11, 2015. ,
Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Experimental and molecular pathology, vol.92, 2012. ,
p53 as a target for the treatment of cancer, Cancer treatment reviews, vol.40, issue.10, 2014. ,
Mutants TP53 p.R273H and p.R273C but not p. R273G enhance cancer cell malignancy, Hum Mutat, vol.35, issue.5, p.24677579, 2014. ,
The impact of R213 mutation on p53-mediated p21 activity, Biochimie, vol.99, pp.215-223, 2014. ,
Assessment of DNA Integrity, Applications for Cancer Research, Advances in clinical chemistry, vol.70, pp.197-246, 2015. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299567
Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomolecular Detection and Quantification, vol.1, pp.8-22, 2014. ,
Circulating tumor cells: liquid biopsy of cancer, Clinical chemistry, vol.59, issue.1, pp.110-118, 2013. ,
Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance, Scientific reports, vol.6, p.4751431, 2016. ,
Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer, Oncotarget, 2016. ,
Detection of circulating tumor DNA in early-and late-stage human malignancies, Science translational medicine, vol.6, issue.224, p.24553385, 2014. ,
, , p.4017867
Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR, Lab Chip, vol.11, issue.13, 2011. ,
URL : https://hal.archives-ouvertes.fr/inserm-02299588